Paul Liknaitzky is Head of Clinical Psychedelic Research at Monash University, and Chief Principal Investigator on a program of psychedelic trials. He is a Research Fellow within both the Dept of Psychiatry (School of Clinical Sciences) and the Turner Institute for Brain and Mental Health (School of Psychological Sciences) at Monash University. He earned an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne, and has Adjunct or Honorary appointments at St Vincent’s Hospital, Macquarie University, Deakin University, and the University of Melbourne. In Australia, he is an Investigator on a number of the country’s initial psychedelic trials, coordinated the first applied psychedelic therapist training programs, obtained the first industry funding for psychedelic science, and leads the first clinical psychedelic lab. His work is focused on developing a rigorous program of research in clinical psychedelics that seeks to evaluate therapeutic effects, innovate on treatment design, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms.